These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 3738857

  • 41. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 42. Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
    Gouin-Thibault I, Dewar L, Kulczycky M, Sternbach M, Ofosu FA.
    Br J Haematol; 1995 Jul; 90(3):669-80. PubMed ID: 7647008
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life.
    Byrnes JW, Swearingen CJ, Prodhan P, Fiser R, Dyamenahalli U.
    ASAIO J; 2014 Jul; 60(1):57-62. PubMed ID: 24296776
    [Abstract] [Full Text] [Related]

  • 47. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y, Boyeldieu D, Stieltjes N.
    Nouv Rev Fr Hematol (1978); 1994 Jul; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [Abstract] [Full Text] [Related]

  • 48. Factor IX and thrombosis.
    Aledort LM.
    Scand J Haematol Suppl; 1977 Jul; 30():40-2. PubMed ID: 267296
    [Abstract] [Full Text] [Related]

  • 49. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
    Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyllopoulos DC, Kosow DP.
    Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD.
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [Abstract] [Full Text] [Related]

  • 52. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC, McMillan CW, White GC, Bergman GE, Saidi P.
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [Abstract] [Full Text] [Related]

  • 53. Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
    Young J, Sawyer J, Jenkins M, O'Brien M, Luchtman-Jones L, Breese EH.
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27719. PubMed ID: 30900794
    [Abstract] [Full Text] [Related]

  • 54. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, Rumley A, Ludlam CA.
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III.
    Schoen P, Wielders S, Petitou M, Lindhout T.
    Thromb Res; 1990 Feb 01; 57(3):415-23. PubMed ID: 2315894
    [Abstract] [Full Text] [Related]

  • 58. The Use of Recombinant Antithrombin III in Pediatric and Neonatal ECMO Patients.
    Todd Tzanetos DR, Myers J, Wells T, Stewart D, Fanning JJ, Sullivan JE.
    ASAIO J; 2017 Feb 01; 63(1):93-98. PubMed ID: 27861430
    [Abstract] [Full Text] [Related]

  • 59. Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion.
    Brandt P.
    Thromb Res; 2017 Feb 01; 22(1-2):15-24. PubMed ID: 7292437
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.